Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balaglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 9/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ESRRA | P11474 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balaglitazone SCHEMBL20125574 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL29362039 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL242011 | 1.00 | PPARG (1.00) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL6359086 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL2567773 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL2567779 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935613 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| Balaglitazone SCHEMBL5935616 | 0.99 | PPARG (0.98) | PPARGFFAR1PPARAKDM4EALOX15 | |
| SCHEMBL5844579 | 0.89 | PPARG (0.80) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL1130955 | 0.88 | PPARG (0.79) | PPARGFFAR1PPARAESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253937-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | POXEL SA (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125827-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DPP4, SLC5A2, GLP1R | PPARG 12/4885FFAR1 1327/4885PPARA 26/4885 |
| US-20200253937-A1 | 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SLC5A2, GLI2, SLC5A1 | PPARG 13/4885FFAR1 1193/4885PPARA 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.